Fraunhofer MEVIS
Fraunhofer MEVIS is a non-profit Fraunhofer Institute that develops AI-driven medical imaging, image-guided therapy, and computational pathology software for hospitals, pharma, and medical device manufacturers, distributing technology via research collaboration and licensing.
- Company typePrivate
- Founded1995
- HeadquartersBremen, Germany
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Fraunhofer MEVIS does
Fraunhofer MEVIS, formally the Fraunhofer Institute for Digital Medicine, is a non-profit applied research institute headquartered on the University of Bremen campus and operating since 1995 as a constituent entity of the Fraunhofer-Gesellschaft. Its work spans medical image computing, AI/ML for medical imaging, image-guided therapy, computational pathology, and radiation therapy planning. The institute develops a portfolio of named software solutions including OncoChange (AI-driven CT-based tumor follow-up), CuraMate and HistokatFusion (computational pathology with digital biomarkers), CaFuR (multicycle real-time cardiac MRI analysis), gammaSTAR (radiation therapy planning and dosimetry), SAFIR (a modular framework for needle-based interventional workflows), the Liver Explorer App (tablet-based surgical planning showcased at an Apple Special Event), MEVIS draw (free analysis tooling), and the NAKO-Viewer (digital infrastructure for Germany's largest population health study).
Technically, the institute combines proprietary algorithms in medical image registration, real-time MRI reconstruction, segmentation, simulation, and visualization with AI/ML pipelines for computer vision, predictive analytics, and — per a Science Advances publication — generative synthesis of radiographs. It is staffed by scientists with dual academic-clinical affiliations, multiple Highly Cited Researchers, and ISMRM Fellows, and operates from a purpose-built 2,600 sqm facility occupied in May 2021 with capacity for 210 workstations, plus a project group in Lübeck.
Commercially, Fraunhofer MEVIS does not sell SaaS or standalone products at list prices. Revenue is generated through a mix of (i) base funding from the Fraunhofer Society (German federal and state government appropriations), (ii) competitive third-party research grants from BMBF, DFG, and EU programs such as ERDF, and (iii) contract research, technology licensing, and co-development with pharmaceutical companies, medical device manufacturers (e.g., imaging oncology platforms), academic medical centers (UKE, University of Bern), and large public health programs (NAKO German National Cohort). Go-to-market is sales-led through collaborative R&D rather than transactional selling, with distribution via technology licensing, joint development, and free tools (MEVIS draw) used as awareness funnels into commercial engagements.
Fraunhofer MEVIS firmographics
Firmographics- Name
- Fraunhofer MEVIS
- Legal name
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Website
- https://mevis.fraunhofer.de
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Fraunhofer MEVIS is a non-profit Fraunhofer Institute that develops AI-driven medical imaging, image-guided therapy, and computational pathology software for hospitals, pharma, and medical device manufacturers, distributing technology via research collaboration and licensing.
- Ownership category
- akta.pro rank
Fraunhofer MEVIS industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Scientific Research and Development Services (5417), Computer Systems Design Services (541512), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where Fraunhofer MEVIS is headquartered
LocationHeadquarters
- HQ city
- Bremen
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Fraunhofer MEVIS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Research Funding: Fraunhofer MEVIS receives core funding from the Fraunhofer Society, which is funded by German federal and state governments. Additional project funding comes from BMBF (Federal Ministry of Education and Research), DFG (German Research Foundation), and EU research programs.
- Industry Collaborations: Collaborative R&D projects with pharmaceutical companies, medical device manufacturers, and healthcare providers for technology development and validation.
- Technology Transfer: Licensing of developed software solutions and algorithms to medical device companies and healthcare technology providers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Fraunhofer MEVIS product offering
Product offeringCore offering
Fraunhofer MEVIS develops software solutions for image- and data-supported early detection, diagnosis, and therapy, spanning medical image computing, AI-driven diagnostics, image-guided therapy planning, and computational pathology. It commercializes these capabilities through research collaborations, contract R&D, and licensing of proprietary algorithms to hospitals, pharmaceutical companies, and medical-device manufacturers, alongside a limited set of free-standing tools (e.g., MEVIS draw).
Product overview
Fraunhofer MEVIS develops real-world software solutions for computer-aided medicine, bridging medical imaging, image-guided therapy, and healthcare informatics. The institute operates as a research and technology transfer organization with a portfolio of named products including diagnostic software solutions (OncoChange for AI-driven tumor follow-up, CuraMate with multiple sub-products for reader studies, education and AI development, HistokatFusion for computational pathology), imaging physics tools (gammaSTAR for radiation therapy), real-time MRI cardiac analysis (CaFuR), and image-guided therapy solutions (SAFIR for needle-based interventions, Liver Explorer App). Additional offerings include free analysis software (MEVIS draw) and digital infrastructure services (NAKO-Viewer for national health studies). The products span diagnostic software, image-guided therapy, clinical trials and pharma support, and computational pathology.
Differentiator
Problem solved
Functional benefit
Brands
- OncoChange: AI-driven software solution that enables radiologists to perform CT-based tumor follow-up assessments in clinical practice more efficiently and reliably.
- HistokatFusion
- CuraMate
- gammaSTAR
- CaFuR
- SAFIR
Products and services
- OncoChange AI-driven software solution that enables radiologists to perform CT-based tumor follow-up assessments in clinical practice more efficiently and reliably, automatically analyzing tumor progression over time.
- CuraMate Comprehensive medical imaging solution with sub-products including CuraMate Reader Studies for clinical research, CuraMate Education for training, and CuraMate AI Development for AI-powered diagnostic tools.
- HistokatFusion Solution for computational pathology combining histological data analysis capabilities.
- gammaSTAR Advanced imaging physics solution for radiation therapy planning and visualization, supporting radiofrequency ablation procedures for liver tumors.
- CaFuR Multicycle real-time MRI analysis software for cardiac diagnosis, consisting of accelerated MRI acquisition and a complete software solution for automated cardiac function analysis that identifies breathing and heart contraction phases independently of ECG information.
- SAFIR Modular framework for software assistance during needle-based interventions, supporting the entire interventional workflow from planning to assessment using segmentation, registration, simulation, optimization, and visualization methodology.
- MEVIS draw Free software tool for medical image analysis and annotation, available for download for Windows, Linux, and macOS platforms.
- NAKO-Viewer Digital infrastructure solution for Germany's largest health study (NAKO), providing medical image data management for the German National Cohort.
- Liver Explorer App Tablet-based application for liver surgeons providing access to and visualization of planning data during liver surgery, originally demonstrated at an Apple Special Event.
Quantifiable outcome
- AI-driven tumor follow-up enables more efficient and reliable CT-based tumor assessments in clinical practice
- +2 more outcomes
Companies that use Fraunhofer MEVIS
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Fraunhofer MEVIS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature10 records
Fraunhofer MEVIS partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Marshmallow Laser Feast (MLF)coreResearch partnership for immersive artwork 'The Tides Within Us' exploring oxygen flow through the human cardiovascular system using VR and immersive technologies. MLF is one of the world's leading immersive art collectives.
- York MedialeminorInternational new media arts charity in York, UK (UNESCO Creative City of Media Arts) collaborating on 'The Tides Within Us' presentation.
- University of BerncoreCooperated with University of Bern and leading liver center in Shanghai on navigated liver surgery research and development.
- U Bremen Research AlliancecoreCollaborative alliance including launch of AI Center for Health Care. Fraunhofer MEVIS perpetuates collaboration with universities in Bremen.
- Leibniz Institute for Prevention Research and Epidemiology (BIPS)coreCollaboration on AI4Prevention position paper addressing disease prevention and early detection through AI.
- University of BremencoreClose research partnerships with University of Bremen including Horst Hahn accepting professorship. NAKO-Viewer development in MR laboratory.
- Harvard Medical SchoolminorPrestigious appointment of MEVIS researcher at Harvard for academic exchange and collaboration.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Fraunhofer MEVIS competitors and assessment
Company assessmentEmerging players
- Arterys: Cloud-native medical imaging AI platform with FDA-cleared cardiac MRI and CT modules; directly comparable to MEVIS's CaFuR real-time cardiac MRI and broader imaging AI efforts.
- Paige.AI: AI-driven computational pathology company developing digital biomarkers from pathology images; directly comparable to MEVIS's CuraMate and HistokatFusion computational pathology programs.
- Aidoc: VC-backed AI imaging company focused on CT workflow triage and radiology AI; directly comparable to MEVIS's OncoChange-style CT-based clinical decision support and AI tumor follow-up capabilities.
Broad incumbents
- Philips Healthcare: Imaging, interventional, and clinical informatics incumbent with AI-enabled diagnostic and image-guided therapy offerings; comparable in product breadth and in serving academic medical centers and large hospital systems in Europe.
- GE HealthCare: Imaging equipment and AI-software incumbent with Edison platform; relevant peer because its radiology AI applications and PACS integrations directly compete with the clinical-use cases MEVIS targets (CT, MRI, oncology follow-up).
- Siemens Healthineers: Global medical imaging and diagnostics incumbent whose AI-Rad Companion and digital health portfolio overlap directly with MEVIS's AI imaging and image-guided therapy R&D; competes as a downstream commercializer of similar algorithms.
Others
- NVIDIA Clara / NVIDIA Healthcare: Compute and developer-platform vendor whose Clara imaging AI toolkit is used by MEVIS researchers (NVIDIA Demo Contest winner) and shapes the ecosystem in which medical-imaging AI is built and deployed.
Direct peers
- Median Technologies: Imaging CRO and AI imaging company focused on oncology trial endpoints and tumor follow-up assessment; directly comparable to MEVIS's OncoChange, computational pathology, and pharma imaging biomarker work for clinical trials.
- German Cancer Research Center (DKFZ): Germany's largest publicly funded biomedical research institute; comparable as a peer applied-research organization with overlapping oncology imaging, radiomics, and AI-driven diagnostics programs that compete for BMBF/DFG funding and academic talent.
- Radboud University Medical Center (Radboudumc): Academic medical center with a globally recognized medical-imaging AI group (e.g., Diagnostic Image Analysis Group); comparable as a research-driven developer of imaging AI algorithms deployed in clinical radiology workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Fraunhofer MEVIS social profiles
Digital presenceFraunhofer MEVIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fraunhofer MEVIS leadership team
Management profileNumber of profiles
Profiles4 records
Fraunhofer MEVIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fraunhofer MEVIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fraunhofer MEVIS
What does Fraunhofer MEVIS do?
Fraunhofer MEVIS develops software solutions for image- and data-supported early detection, diagnosis, and therapy, spanning medical image computing, AI-driven diagnostics, image-guided therapy planning, and computational pathology. It commercializes these capabilities through research collaborations, contract R&D, and licensing of proprietary algorithms to hospitals, pharmaceutical companies, and medical-device manufacturers, alongside a limited set of free-standing tools (e.g., MEVIS draw).
Is Fraunhofer MEVIS a public or private company?
Fraunhofer MEVIS is a private company. It is classified as state government owned and is currently operating.
When was Fraunhofer MEVIS founded?
Fraunhofer MEVIS was founded in 1995. It employs 51 to 100 people.
Where is Fraunhofer MEVIS based?
Fraunhofer MEVIS is headquartered in Bremen, Germany, in the Europe region.
How does Fraunhofer MEVIS make money?
Three revenue lines are on record. Research Funding is the primary driver. The others are industry Collaborations and technology Transfer.
Who are Fraunhofer MEVIS's main competitors?
Emerging players on record are Arterys, Paige.AI and Aidoc. Broad incumbents are Philips Healthcare, GE HealthCare and Siemens Healthineers. NVIDIA Clara / NVIDIA Healthcare is listed as an others. Direct peers are Median Technologies, German Cancer Research Center (DKFZ) and Radboud University Medical Center (Radboudumc).
Does Fraunhofer MEVIS have an API?
No public API is recorded for Fraunhofer MEVIS.
What industry is Fraunhofer MEVIS in?
Fraunhofer MEVIS's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5417 and its SIC code is 8731.